Optimizing Outcomes in Myeloma

About this episode

This episode discusses optimizing outcomes in myeloma with experts in the field.

Amy Pierre, MSN, ANP-BC, Flatiron Health and Memorial Sloan Kettering, New York, NY and Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC Recorded on March 10, 2026 Amy Pierre, MSN, ANP-BC Senior Clinical Director, Research Oncology, Flatiron Health Nurse Practitioner, Memorial Sloan Kettering Cancer Center New York, NY Peter Voorhees, MD Director, Outreach for Hematologic Malignancies, Plasma Cells Disorder Program, Department of Hematologic Oncology and Blood Disorders Levine Cancer Institute Charlotte, NC Professor, Cancer Medicine Wake Forest University School of Medicine Winston-Salem, NC In this episode, Dr. Peter Voorhees from the Levine Cancer Institute and Amy Pierre, MSN, RN, ANP BC from Flatiron Health and Memorial Sloan Kettering, break down the evolving landscape of myeloma, from early signs and diagnostic criteria to frontline therapy, transplant decisions, and T- cell redirecting therapies. They explore real world challenges in survivorship, treatment toxicity, and disparities in access to advanced therapies, offering practical insights to help care teams support patients more effectively. Tune in for an informative and forward looking discussion shaping…

People in this episode

Guests: Amy Pierre Msn Anp-Bc, Peter Voorhees Md

Topics covered

• Myeloma
• Blood Cancer
• Oncology
• Hematologic Malignancies

Keywords

• treatment
• patient outcomes
• clinical research

Mentioned in this episode

Places: New York, NY, Charlotte, NC, Winston, Salem

More episodes of Treating Blood Cancers

• Optimizing HSCT in Blood Cancers · June 2, 2026 · 39 min
• Clinical Strategies for Supporting Couples, Care Partners, and Families in Oncology Care · May 8, 2026 · 35 min
• Driving Progress in AML · April 23, 2026 · 34 min
• Redefining Normal: Clinical Insights for Healthcare Professionals Supporting Survivors After Treatment · April 13, 2026 · 34 min
• Strategies to Navigate Expanded Access (Compassionate Use) in Treating Pediatric Oncology · March 3, 2026 · 40 min
• What’s New and What’s Next in CLL · February 17, 2026 · 39 min